N-Acetyl Cysteine (NAC) for Parkinson's Disease
Also known as: NAC, Acetylcysteine
Glutathione is severely depleted in Parkinson's substantia nigra, making NAC-driven GSH restoration a targeted therapeutic strategy.
Mechanism of Action
NAC provides the rate-limiting cysteine for glutathione synthesis in dopaminergic neurons. It reduces oxidative stress from dopamine metabolism, protects against mitochondrial Complex I inhibition, and modulates neuroinflammatory signaling.
General mechanism: Cysteine prodrug for glutathione synthesis. Direct ROS scavenger. NMDA receptor modulator. NF-κB inhibitor.
Current Evidence
IV NAC studies show increased brain glutathione on MRS imaging in PD patients. Combined IV+oral NAC protocol showed improved dopamine transporter binding on DaTscan. Results encouraging but small sample sizes.
Clinical Status: Phase II studies positive for brain GSH restoration. IV+oral protocols under investigation.
Safety Profile
Very safe. GI effects common with oral use. IV administration well-established (acetaminophen protocol). Rare: bronchospasm in asthmatics.
Key Research Questions
- Does NAC-mediated GSH restoration correlate with clinical improvement in PD?
- Can NAC slow dopamine transporter loss measured by DaTscan?